antagonist with potent anti-HIV activity that currently is being evaluated in phase III clinical trials. In the present study, donor CCR5 density (CCR5 receptors/CD4 lymphocytes) inversely correlated with VCV antiviral activity (Spearman's correlation test; r ‫؍‬ 0.746, P ‫؍‬ 0.0034). Low doses of the transplant drug rapamycin (RAPA) reduced CCR5 density and enhanced VCV antiviral activity. In drug interaction studies, the RAPA/VCV combination had considerable antiviral synergy (combination indexes of 0.1-0.04) in both multicycle and single-cycle infection of lymphocytes. The synergy between RAPA and VCV translated into dose reduction indexes of 8-to 41-fold reductions for RAPA and 19-to 658-fold reductions for VCV. RAPA enhanced VCV antiviral activity against both B and non-B clade isolates, potently suppressing clade G viruses with reported reduced sensitivities to VCV and to the licensed CCR5 antagonist maraviroc. Importantly, RAPA reduction of CCR5 density in lymphocytes sensitized VCV-resistant strains to VCV, inhibiting virus production by ϳ 90%. We further demonstrated the role of CCR5 density on VCV activity against resistant virus in donor lymphocytes and in cell lines expressing varying CCR5 densities. Together, these results suggest that low doses of RAPA may increase the durability of VCV-containing regimens in patients by enhancing VCV viral suppression, by allowing the use of lower doses of VCV with reduced potential for toxicity, and by controlling emerging VCV-resistant variants.
H
ighly active antiretroviral therapy (HAART) has improved treatment of HIV-1 infected individuals considerably (1) . However, the success of current therapies is limited by the emergence of drug-resistant strains, the need for sustained adherence to complex regimens, and the potential for drug toxicity (2, 3) . The two new antiretroviral classes of integrase and entry inhibitors may help overcome some of the current limitations of HAART (4, 5) . Entry inhibitors are especially attractive because they target HIV at the earliest step of the viral cycle and are effective against strains resistant to inhibitors of protease and reverse transcriptase. Entry inhibitors interfere with HIV binding to CD4 receptor (attachment inhibitors) or chemokine (C-C motif) receptor 5 (CCR5)/chemokine (C-X-C-motif) receptor 4 (CXCR4) coreceptors (coreceptor antagonists) or by preventing fusion between cellular and viral membranes (fusion inhibitors) (5) . Currently, the fusion inhibitor T-20 (enfuvirtide) and the CCR5 antagonist maraviroc (Selzentry) are the only licensed entry inhibitors (6, 7) . The CCR5 antagonist vicriviroc (VCV) presently is in phase III clinical trials (8) . Coreceptor CCR5 antagonists inhibit CCR5-tropic HIV-1 (referred to as ''R5 HIV-1'') strains, which are responsible for most transmissions and generally are present throughout the course of infection. In normal individuals, CCR5 density (receptors/cell) on CD4 lymphocytes ranges between ϳ 2 ϫ 10 3 and ϳ 10 ϫ 10 3 (9) (10) (11) (12) , and this variation influences disease progression and response to therapy in HIV-1 infection (11, 13) .
We previously have demonstrated that low doses of the transplant drug rapamycin (RAPA) reduce CCR5 density, inhibit R5 HIV-1, and enhance T-20 antiviral activity (14, 15) . In the present study we show that the combination of RAPA and VCV has considerable antiviral synergy. Moreover, the RAPA/ VCV combination is active against VCV-resistant HIV-1. These findings suggest the use of RAPA in patients as a strategy for enhancing the antiviral activity of VCV and perhaps of other CCR5 antagonists as well.
Results
Impact of CCR5 Density on the Antiviral Activity of VCV. We first evaluated the effect of CCR5 levels on the antiviral activity of VCV using cell lines JC10 (ϳ 2 ϫ 10 3 CCR5/cell) and JC57 (ϳ 9 ϫ 10 3 CCR5/cell), which express CD4 levels similar to those in normal CD4 T cells and whose CCR5 densities correspond to the approximate lower and upper levels of CCR5 expression in donors (9) (10) (11) (12) . We infected each clone with the R5 HIV-1 strains JRFL and CC1/85 (multiplicity of infection, MOI ϭ 0.01) in the presence of varying concentrations of VCV (0.03-30 nM) for 3 h. For comparison, cells also were infected in the presence of the reverse transcriptase inhibitor efavirenz (0.003-3 nM). On day 4 after infection, HIV-1 p24 levels in the culture supernatants were determined by ELISA (National Cancer Institute). VCV inhibited HIV-1 JRFL replication in the JC-10 and JC-57 clones with EC 50 values of 0.02 and 0.25 nM, respectively (Fig. 1A) . In contrast, EC 50 values for efavirenz were similar (less than twofold change) in both cell lines (data not shown). Similar results were obtained with HIV-1 CC1/85 (data not shown). These data suggest that variations in CCR5 density within the range observed in most individuals (ϳ 2 ϫ 10 3 -1 ϫ 10 4 receptors/ CD4 T cell) greatly affect the antiviral activity of VCV.
We next evaluated the effect of CCR5 density on VCV activity in infectivity assays using lymphocytes from different donors as target cells. Coreceptor CCR5 density was quantified for each donor cell by quantitative flow cytometry analysis. Cells were infected with the R5 strain HIV-1 JRFL (MOI ϭ 0.001) for 3 h in the presence of varying concentrations of VCV. Virus production was measured on day 5 after infection by p24 levels in the supernatants. Results are summarized in Fig. 1B . Among different donors, CCR5 density on CD4 T cells varied between 1.9 and 7 ϫ 10 3 CCR5 receptors/cell. In contrast, measured CD4 density values were similar among the donors (range of 22.4-27.0 ϫ
10
3 CD4 receptors/cell) (data not shown). These density values for CCR5 and CD4 are within the ranges reported by others (9) (10) (11) (12) . Interestingly, VCV EC 50 values varied ϳ 20-fold among the different donors and correlated positively with CCR5 densities (Spearman's correlation test; r ϭ 0.746, P ϭ 0.0034). A similar correlation between CCR5 density and VCV EC 50 was obtained using HIV-1 CC1/85 (data not shown). In a control experiment assessing the donor cells' ability to support virus replication, we infected cells with the X4 strain HIV-1 IIIb and found p24 values varying by less than threefold among the different donors (data not shown). Together, these results using donor cells (Fig. 1B) suggest that variations of CCR5 density among individuals considerably affect the antiviral activity of VCV.
The Antiviral Activities of RAPA and VCV Are Synergistic. The results described in the preceding paragraph ( Fig. 1) suggested that reduction of CCR5 density on cells could increase VCV potency. We previously have shown that the immunomodulatory drug RAPA reduces CCR5 density on CD4 lymphocytes (14) . We thus assessed the antiviral activity of VCV against HIV-1 JRFL in peripheral blood mononuclear cells (PBMCs) cultured in the presence of RAPA. As a control, RAPA was used in combination with efavirenz, a drug that acts intracellularly. Results are shown in Fig. 2 . In the absence of VCV or efavirenz, RAPA inhibited viral replication by up to ϳ 80%, in agreement with our previous studies (14) . In combination with 1 nM RAPA, the amount of VCV required to inhibit virus by 50% was reduced by approximately fivefold (from 0.5 to 0.15 nM), whereas the amount of efavirenz required for the same effect changed only slightly (from 0.4 to 0.3 nM) (Fig. 2 A) . Cell viability, assessed by MTT assays on day 5 after infection, was not affected by RAPA (Fig. 2B ). Similar differences between the RAPA/VCV and RAPA/efavirenz combinations were demonstrated using HIV-1 CC1/85 (data not shown). These results suggested that RAPA had a greater impact on VCV antiviral activity than on efavirenz antiviral activity.
To quantify and compare the effect of RAPA on VCV and efavirenz activities, we next performed drug interaction studies using the Median Effect Principle (16) . To that end, we infected PBMCs with HIV-1 JRFL (MOI ϭ 0.001) in the absence or presence of both drugs (alone and in combination) over a range of concentrations using a checkerboard design. Drugs were tested at threefold dilutions (0.01-3 nM range for RAPA and 0.045-100 nM range for VCV). The antiviral data (p24 production) were analyzed for synergy by determining combination indexes (CI) at RAPA/VCV ratios of 3/10 and 3/100. We chose these drug ratios based on previous determinations of EC 50 values for each drug. Data were analyzed using the CalcuSyn software, and results are summarized in Table S1 . When used alone, RAPA and VCV inhibited virus replication with dose at 50% inhibition (Dm, equivalent to EC 50 ) values of 0.25 and 2.78 nM, respectively. However, when combined at a RAPA/VCV ratio of 3/10, the Dm value for RAPA was reduced to 0.03 nM, and the Dm value for VCV was reduced to 0.10 nM. These reductions in Dm values for each drug suggested a synergistic interaction. The corresponding CI values for the combination ranged from 0.174 to 0.048. Because CI values Ͻ 1 indicate synergy, and values are proportional to the amount of synergy, the CI values obtained for the RAPA/VCV combination represent a high degree of synergy between the drugs (Table S1 ). This synergy translated into dose reduction index values of an 8-to 41-fold reduction for RAPA and a 19-to 658-fold reduction for VCV. A similar degree of synergistic interaction was obtained using a RAPA/VCV ratio of 3/100 (data not shown). In contrast, the CI values for the RAPA/efavirenz combination (3/10 ratio) ranged from 0.9-1.2, suggesting only an additive interaction between the drugs.
The antiviral activity of RAPA/VCV was assessed further in a single-cycle replication assay based on the infection of lymphocytes with an HIV luciferase reporter virus pseudotyped with the R5 JRFL envelope (Env). Cells were infected in the presence of RAPA and VCV, alone and in combination, as described previously in the p24 multicycle replication assay. Pseudovirus replication was determined on day 3 after infection by determining luciferase levels in cell lysates. Data then were analyzed for synergy using the median-effect principle, and CI values were determined. When RAPA/VCV were tested at ratios of 3/10 and 3/100, the CI values ranged from 0.194-0.012 and from 0.189-0.04, respectively. In contrast, CI values for RAPA/efavirenz were ϳ 1, suggesting additivity. These results are similar to those from the multicycle p24 assay and further demonstrate synergy between RAPA and VCV.
The results of the multicycle and single-cycle infectivity assays show that RAPA synergizes with the entry inhibitor VCV. To evaluate the impact of the RAPA/VCV combination in the early steps of viral entry, we tested the drug combination in a cell-cell fusion assay (17) . RAPA-treated lymphocytes and HIV-1 JRFL Env-transfected cells were stained with fluorescent dyes and incubated in the presence of VCV, as described in Methods. Inhibition of cell-cell fusion was evaluated by flow cytometry. We evaluated each RAPA concentration in combination with threefold dilutions of VCV. Results are shown in Fig. 3 . The VCV EC 50 values at 0, 0.1, 0.3, and 1 nM RAPA were 4.1, 1.9, 0.6, and 0.003 nM, respectively. Comparable reductions in VCV EC 50 were observed using cells expressing HIV-1 CC1/85 Env (data not shown). These reductions of VCV EC 50 values in the presence of RAPA are consistent with the results obtained in the multicycle (p24) and single-cycle (luciferase) infectivity assays and demonstrate that the RAPA/VCV combination acts early in viral entry.
RAPA Enhances the Antiviral Activity of VCV Against R5 HIV-1 Isolates
from Different Clades. The experiments described in the previous paragraphs were conducted using the HIV-1 clade B strains JRFL and CC1/85, which have been used frequently in studies evaluating entry inhibitors (18, 19) . Because of the remarkable variability in sequence diversity among HIV-1 clades, we also evaluated the antiviral activity of RAPA/VCV in viruses from non-B clades. For these experiments, we tested the RAPA/VCV combination in PBMCs using replication-competent viral strains. Serial dilutions of VCV were tested in the presence of RAPA concentrations of 0, 0.1, 0.3, and 1 nM. Virus production (p24 levels) and cell viability (MTT assay) were determined on day 5 after infection. Results are summarized in Table S2 . In the absence of RAPA, VCV EC 50 values ranged from 0.09-10 nM.
The three clade G isolates tested (RU570, JV1083, and G3) presented the highest EC 50 values, in agreement with previous reports demonstrating reduced sensitivity of clade G viruses to VCV (18, 19) . In the presence of RAPA concentrations of 0.1, 0.3, and 1 nM, VCV EC 50 values were reduced by up to 7.5-, 10-, and 60-fold, respectively. Cell viability was not affected (not shown). These results demonstrate that RAPA enhances the antiviral activity of VCV against isolates from different clades. (20) . It is strictly dependent on CCR5 as coreceptor and uses VCV-bound CCR5, albeit less efficiently than free CCR5 (21) . Based on D1/85.16 dependence on CCR5 for infection, we reasoned that RAPA could reduce D1/85.16 infection by decreasing CCR5 density. In addition, reduction of CCR5 density by RAPA would increase the proportion of CCR5 receptors occupied by VCV and possibly further reduce the overall efficiency of D1/85.16 infection. To test this possibility, we infected 7-day RAPA-treated PBMCs with a replication-competent D1/ 85.16 molecular clone in the presence of varying concentrations of VCV and measured p24 production on day 5 postinfection. At the time of infection, cells treated in the absence and presence of RAPA (0.1, 0.3, and 1 nM) yielded CCR5 density values of 5318, 3900, 3535, and 2791 coreceptors/CD4 T cell, respectively. As expected from previous studies (20, 21) , VCV alone had no impact on virus replication (Fig. 4) , probably reflecting viral use of VCV-bound CCR5 for infection. In contrast, RAPA alone reduced viral replication by 30% to 60%, consistent with viral dependence on CCR5. Interestingly, when RAPA and VCV were combined, VCV further increased the RAPA antiviral effect to ϳ 70% to 90%. Cell viability, as determined by MTT assays, was not affected by the drugs (data not shown). These results suggest that VCV-resistant HIV becomes partially sensitive to VCV when CCR5 density decreases.
To investigate a possible relationship between CCR5 density and the antiviral activity of VCV against VCV-resistant HIV-1, we evaluated the antiviral effect of 300 nM VCV in donors expressing different CCR5 densities. As a control, the antiviral effect also was determined on the sensitive HIV-1 CC1/85 strain. As expected, 300 nM VCV completely inhibited HIV-1 CC1/85 in all donors (Fig. 5) . In contrast, HIV-1 D1/85.16 resistance to VCV was affected by donor CCR5 density, with partial viral inhibition observed at decreased CCR5 densities. In a control experiment assessing HIV-1 IIIb (X4 HIV-1) replication, similar p24 levels were obtained in all donors (data not shown). These results demonstrate that CCR5 density affects the resistance of HIV-1 D1/85.16 to VCV and further suggest that the RAPA effect on VCV activity against resistant virus results from decreases in CCR5 density.
We next investigated the effect of CCR5 density on VCV activity against VCV-resistant HIV-1 by infecting cell lines that express same CD4 levels but varying CCR5 densities with replication-defective pseudoviruses bearing Env from CC1/85 (VCV-sensitive) and D1/85.16 (VCV-resistant) clones. We used JC57 (ϳ 9 ϫ 10 3 CCR5/cell) and JC10 (ϳ 2 ϫ 10 3 CCR5/cell) cells, which express CCR5 densities corresponding to the approximate upper and lower limits of CCR5 expression on primary cells. For comparison, we also used JC53 (ϳ 160 ϫ 10 3 CCR5/cell), which overexpresses CCR5. We confirmed these CCR5 density values by quantitative flow cytometry analysis. As expected, VCV completely inhibited CC1/85 pseudovirus infection (data not shown). In contrast, VCV inhibition of D1/85.16 pseudovirus infection was incompletely inhibited, with maximal inhibition plateaus of 18-and 265-fold for JC53 and JC57, respectively (Fig. S1 A, Left) . Interestingly, VCV inhibited D1/ 85.16 pseudovirus infection of JC-10 cells by ϳ 800-fold, to levels that were undistinguishable from background (determined by fully inhibitory concentrations of T-20 and efavirenz). These results clearly confirm that D1/85.16 resistance to VCV depends upon CCR5 density and suggest that VCV can inhibit VCVresistant HIV infection at low CCR5 densities. We confirmed the results obtained with D1/85.16 pseudovirus using the Env from HIV-1 CC101.19, another VCV-resistant virus (20, 22, 23) . We prepared pseudoviruses bearing the Env of CC101.19 and infected the same JC clones as before plus JC37 (ϳ 15 ϫ 10 3 CCR5/cell) and JC24 (ϳ 90 ϫ 10 3 CCR5/cell). Both JC37 and JC24 express same CD4 densities as the other JC clones. Results are similar to those with D1/85.16 ( Fig. S1 A, Right) . Normalization of inhibition plateaus to infectivity values in the absence of drug for each cell line yielded 40%, 80%, 92%, 95%, and 100% inhibition for JC53, JC24, JC37, JC57, and JC10, respectively. These data demonstrate that VCV inhibition of VCV-resistant viruses correlates with CCR5 density. In addition, as in the results obtained with HIV-1 D1/85.16 pseudoviruses, VCV abrogated infection of JC10 by HIV-1 CC101.19 pseudoviruses. Together, these results in cell lines confirm the association between VCV activity against resistant HIV and CCR5 density observed in primary cells. However, the results in cell lines demonstrate that VCV can overcome viral resistance at low CCR5 density (ϳ 2 ϫ 10 3 CCR5/cell, JC10 cells) but only partially (ϳ 90%) overcomes resistance in primary cells expressing CCR5 densities similar to those in JC10 (either in donors with low CCR5 expression or following RAPA treatment (Fig.  4 and Fig. 5 ). To determine the basis for this discrepancy, we evaluated the antiviral activity of VCV in JC10 cells using the replication-competent HIV molecular clones used in the PBMC assay. Virus production was measured by p24 on day 5 after infection. VCV completely inhibited sensitive virus (HIV-1 CC1/85) as determined by p24 levels (Ͻ 6 pg/ml, the assay sensitivity limit) (Fig. S2) . However, in contrast to the results from pseudovirus infections, VCV inhibited resistant viruses D1/85.16 and CC101.19 molecular clones by ϳ 90% and 80%, respectively. These results indicate that VCV inhibition of resistant virus in cells with low CCR5 density (ϳ 2 ϫ 10 3 CCR5 cells) depends upon the type of assay used.
Discussion
Coreceptor CCR5 antagonists are a new class of antiretroviral agents with a unique mechanism of action that offer additional treatment options to patients, especially those infected with drug-resistant HIV-1 (5) . In the present study we evaluated the effect of CCR5 density and its modulation by RAPA on the antiviral activity of the CCR5 antagonist VCV using primary cells.
We demonstrate that CCR5 density (CCR5 receptors/CD4 lymphocyte) in donors inversely correlates with VCV potency. Specifically, VCV EC 50 values were ϳ 20 times higher in donors with ϳ 7 ϫ 10 3 CCR5 molecules/cell than in donors with ϳ 2 ϫ 10 3 CCR5 molecules/cell. Previous studies with cell lines have shown that CCR5 levels influence the antiviral activity of the CCR5 antagonist TAK-779, with higher CCR5 levels resulting in reduced antagonist activity (24) (25) (26) . Ketas et al. (27) have shown recently that donor variation in CCR5 levels (determined by mean fluorescence intensity) correlates with the antiviral activity of VCV. We extended these previous studies by showing that donor CCR5 density (number of receptors/CD4 lymphocyte) correlates with sensitivity to VCV.
We further show that RAPA, a drug that downregulates CCR5 density on lymphocytes (14) , greatly enhances VCV activity against R5 HIV-1. In drug-interaction studies, RAPA/ VCV combinations demonstrated considerable synergistic activity that translated into VCV dose reductions of up to 650-fold. RAPA enhanced VCV antiviral activity against primary strains of both B and non-B clades. Of note, the combination of RAPA and VCV was especially potent against clade G isolates, which have reduced sensitivities to VCV (19) and maraviroc (18) . At a concentration of 1 nM, RAPA reduced VCV EC 50 values by 30-to 60-fold against the tested clade G isolates. These experiments were conducted in PBMCs pretreated with RAPA for 7 days because under these conditions RAPA-treated cells express reduced CCR5 density (15) . It is possible that RAPA will reduce CCR5 at earlier time points, but this effect is difficult to determine because Ficoll separation of PBMCs alters coreceptor expression levels, which are not restored until after several days in culture with IL-2 (28, 29). Although we have observed CCR5 downregulation by day 7, our results indicate that CCR5 downregulation in the presence of RAPA is sustained by day 14 of culture (not shown). Moreover, in vivo administration of RAPA for 12 weeks resulted in sustained downregulation of CCR5 levels in macaques (30) .
It is thought that HIV requires the engagement of several (about four to six) CCR5 molecules to form a fusion pore (31) . We postulate that RAPA reduction of CCR5 density could prevent R5 HIV virions from engaging a minimum number of CCR5s required for effective fusion. In the RAPA/VCV combination, reduction of CCR5 density and partial blocking of CCR5 by VCV would effectively prevent CD4 bound viral envelopes from engaging sufficient CCR5 molecules. As a result, CD4-triggered envelopes unable to progress in the entry cascade would be exposed for prolonged periods of time and subjected to inactivation (24) . We currently are investigating these mechanisms in an effort to characterize the basis for antiviral synergy by the RAPA/CCR5 antagonist combination.
We also have shown that RAPA reduction of CCR5 density on lymphocytes decreased VCV-resistant HIV-1 D1/85.16 replication and, in combination with VCV, inhibited viral replication by ϳ 90%. These results suggested that VCV can regain antiviral activity against VCV-resistant HIV when CCR5 density is reduced by RAPA treatment. Consistent with this notion, we found that the extent of HIV-1 D1/85.16 resistance to VCV in primary cells was affected by donor CCR5 density, with VCV partially inhibiting VCV-resistant virus in those donors with lower densities. Previous studies using viruses resistant to VCV (21) and maraviroc (32) have shown that titration of drug against the resistant virus in phytohemagglutinin-activated PBMCs gives flat inhibition curves. Our results in IL-2-stimulated PBMCs (without use of mitogens) reveal that the shape of the inhibition curves is affected by the density of CCR5, suggesting that flat inhibition curves observed in previous studies reflect a higher cellular activation state that leads to CCR5 overexpression. We confirmed the impact of CCR5 density on resistant virus resistance to VCV in single-cycle infectivity assays using pseudovi-ruses bearing Env from two different VCV-resistant viruses (D1/85.16 and CC101.19 strains) and cell lines expressing varying CCR5 densities. In these assays, we demonstrated that the magnitude of the maximal inhibition plateau depends on CCR5 density, with greater inhibition in cell lines with lower CCR5 densities. Interestingly, VCV potently inhibited VCV-resistant HIV in JC10 cells that express CCR5 levels (ϳ 2 ϫ 10 3 CCR5/cell) similar to those in primary cells treated with RAPA. However, the extent of VCV inhibition of resistant virus at low CCR5 density was greater in pseudovirus infection of cell lines (Ͼ 99%) than in infection of PBMCs with replication-competent molecular clones (ϳ 90%). Subsequent experiments evaluating the antiviral activity of VCV against replication-competent resistant viruses in JC10 cells suggested that the greater inhibition observed in cell lines is not likely to be caused by differences in CCR5 levels between cell types but rather by the modality of the assay (single-cycle versus multicycle infection). Similar differences in drug antiviral activity in the two infectivity assays have been reported recently by Heyndrickx, et al. (33) . We believe that infectivity assays using replication-competent HIV and primary PBMCs are more relevant to physiologic conditions. Collectively, these findings may have relevant clinical implications for the use of VCV, and perhaps maraviroc, in the treatment of HIV-1 infection. Based on guidelines currently available for maraviroc (34) , it is likely that VCV will be recommended for use in combination with other antiretrovirals in treatment-experienced patients infected with R5 HIV-1. Our findings suggest the potential clinical utility of RAPA in VCVcontaining drug regimens as an approach to reduce CCR5 density and enhance VCV activity against both VCV-sensitive and VCV-resistant R5 HIV-1. Because CCR5 density and VCV EC 50 are positively correlated, and RAPA reduces CCR5 density to ϳ 2 ϫ 10 3 CCR5/CD4 T cell (15) , it is conceivable that RAPA enhancement of VCV activity will be more apparent in subjects with higher CCR5 levels. The fact that immune activation in HIV patients upregulates CCR5 expression (35) suggests that RAPA will enhance VCV activity significantly in patients. For reference purposes, it is interesting that patient dosing with 10, 25, and 50 mg VCV yields C max values of 58, 150, and 304 nM, respectively, and potent viral suppression (8) . In transplant patients RAPA plasma levels range from 1 to 10 nM. In our studies, testing of RAPA/VCV at ratios of 3/10 and 3/100 revealed significant antiviral synergy, suggesting that dosing with low (1 nM) RAPA plasma levels and low (58 nM) VCV plasma levels would result in a RAPA/VCV ratio of 1/58, which is similar (Ͻ twofold lower) to the 3/100 ratio shown to have considerable synergy in our experiments.
There is a reasonable concern that the use of CCR5 antagonists in patients with R5 HIV-1 may induce viral mutations allowing CXCR4 coreceptor use (X4 strains). Results from both VCV and maraviroc trials in patients infected with R5 HIV-1 indicate that X4 variants can be detected in some patients who do not respond to antagonist treatment. However, genotypic analyses suggest that such X4 variants already were present, although at an undetectable frequency, before treatment, and that their presence became evident after suppression of the dominant R5 strains (36, 37) . Thus, therapy with a CCR5 antagonist may select for pre-existing X4 strains but does not seem to induce evolution of R5 to X4 strains. Moreover, preliminary results show absence of immunological deterioration in patients who have detectable X4 strains and do not respond to maraviroc treatment, suggesting that more pathogenic viruses are not be selected under antagonist pressure (38, 39) . In any event, it is likely that a drug regimen containing RAPA and VCV will be effective in preventing the emergence and replication of X4 strains, because RAPA inhibits both R5 and X4 viral gene expression (40) . Furthermore, RAPA and VCV will be best used in combination with other antiretrovirals active against both R5 and X4 HIV-1.
RAPA currently is used as an immunosuppressant in kidney transplantation at concentrations ranging from 1-10 nM (41) . Several studies in HIV-infected individuals receiving kidney transplants and treated with both antiretrovirals and RAPA suggest that RAPA use in HIV patients is safe (42) (43) (44) . Our data (14, 15) and those of others (40) demonstrate that RAPA concentrations in the 0.1-1 nM range inhibit HIV and synergize with VCV (this report) in the absence of cell toxicity in vitro, suggesting that RAPA doses lower than the ones used in transplantation will be effective against HIV in patients. Synergistic enhancement of VCV antiviral activity by RAPA may allow the use of a lower VCV effective dose in patients, thus minimizing potential drug toxicities such as hepatotoxicity (34, 45, 46) . VCV dose reductions may prove particularly beneficial in the treatment of HIV patients co-infected with hepatitis C virus or hepatitis B virus (up to 50% of HIV patients in regions where the viruses coexist), because these patients are more likely to experience hepatotoxicity (47) . In addition, the RAPA/VCV combination may provide a valuable treatment option for HIV patients diagnosed with end-stage renal disease and undergoing kidney transplantation, because these patients need treatment with both immunosuppressants and antiretrovirals (44, 48) . Moreover, our results demonstrating that the RAPA/VCV combination is active against VCV-resistant HIV suggest that therapeutic modulation of CCR5 density may help control HIV resistance to VCV in patients. Together, these results suggest that low doses of RAPA may increase the durability of VCV-containing regimens in patients by enhancing VCV viral suppression, by allowing the use of lower doses of VCV with reduced potential for toxicity, and by controlling emerging VCV-resistant variants.
Methods
Quantification of CD4, CCR5, and CXCR4. Quantification of CCR5, CXCR4 and CD4 was done using Quantibrite-PE beads, as described in SI Methods.
Cell Culture, Viruses, and Inhibitors. Conditions for tissue culture (PBMCs, HEK 293 T, and HeLa), viruses, and drugs are described in SI Methods.
Multicycle Infectivity Assay. For infection of PBMCs, cells were cultured in medium containing IL-2 (100 U/ml) and different concentrations of RAPA for 7 days. On day 7, cells were exposed to infectious virus for 2 h. Non-adsorbed virus was removed by washing cells with PBS three times. Infected cells were cultured in IL-2 medium in the presence of drugs. Unless otherwise indicated, PBMCs were infected using an MOI of 0.001. Virus growth was monitored in culture supernatants by measuring p24 antigen levels by ELISA (National Cancer Institute) on day 4 after infection.
Single-Cycle Infectivity Assay. Replication-defective HIV-1 reporter viruses were produced by co-transfecting 2 ϫ 10 6 293T cells with 10 g of pNL4.3-env Ϫ -luc3 and 10 g of Env expression vectors (pSV-JRFLenv, pCI-CC1/85, pCI-D1/85.16, pCI-CC101.19, or pSV-HXB2env [X4]) using the calcium phosphate protocol, as described (17) . Pseudoviruses were collected 48 h after transfection, spun to remove cellular debris, and filtered to remove virus clusters. Virus quantification was by p24 by ELISA. For infection, cells were mixed with pseudovirus at a ratio of 10 ng p24/2 ϫ 10 5 cells. Luciferase activity was measured at 72 h by luminometry using the Luciferase Assay System (Promega). Assay background signal was determined by measuring luciferase activity upon cell infection in the presence of fully inhibitory concentrations of T-20 (10 M) or reverse transcriptase inhibitor efavirenz (100 nM), and typically was 30 -100 luciferase units. For normalization of infectivity data, this background signal was subtracted from the signal obtained in the absence of T-20 or efavirenz.
Cell-Cell Fusion Entry Assay. We used a cell-cell fusion assay that is based on cytoplasmic dye exchange mediated by HIV-1 envelope glycoprotein (49) . The extent of cell fusion was quantified by flow cytometry, as described previously (17) . The cell-cell fusion assay and the data analysis are described in SI Methods.
